ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 605,53
0,45%
Dow Jones
38 778,10
0,49%
DAX
18 122,27
0,27%
Brent Oil
83,765
-0,16%
Bitcoin
65 249,79
-1,86%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Apollomics Inc (APLMW)

  7. Apollomics Inc (APLMW) Actualités

APLMW Apollomics Inc

0,01555
0,00 (0,00%)
Avant marché
Dernière mise à jour : 13:00:05
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Apollomics Inc APLMW NASDAQ Warrant
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 0,01555 13:00:05
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,01555
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
04/6/202414:00GLOBEApollomics Announces Vebreltinib Data at the 2024 American..
30/5/202422:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/5/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
29/5/202423:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
29/5/202414:00GLOBEApollomics Announces Presentation at the 2024 BIO..
24/5/202423:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/5/202422:58EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/5/202422:32EDGAR2Form F-3 - Registration statement by foreign private issuers
20/5/202422:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/5/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/5/202422:05GLOBEApollomics Announces Private Placement Financing and..
25/4/202414:30GLOBEApollomics Announces Approval of Vebreltinib in China as a..
10/4/202413:00GLOBEApollomics Presents Vebreltinib Data at the 2024 American..
02/4/202414:00GLOBEApollomics Announces Poster Presentations of Vebreltinib..
28/3/202412:00GLOBEApollomics Highlights Clinical Progress and Reports Full..
26/3/202413:00GLOBEApollomics to Announce Full Year 2023 Financial Results and..
04/3/202413:00GLOBEApollomics Appoints Matthew Plunkett, Ph.D. as Chief..
07/2/202413:00GLOBEApollomics to Present at the Oppenheimer 34th Annual..
19/1/202422:15GLOBEApollomics Receives Nasdaq Notification Regarding Minimum..
17/1/202422:30GLOBEApollomics to Participate in a Fireside Chat at the B. Riley..
03/1/202413:00GLOBEApollomics Completes Enrollment in Phase 3 Bridging Study of..
02/1/202422:30GLOBEApollomics to Present at the 2024 Biotech Showcase
04/12/202313:00GLOBEApollomics Presents Interim Data from Two Ongoing Phase 2..
29/11/202313:30GLOBEApollomics to Participate in a Fireside Chat at the H.C...
28/11/202313:00GLOBEApollomics Announces Presentation of Vebreltinib Data at the..
16/11/202314:30GLOBEApollomics Announces the First Approval of Vebreltinib for..
31/10/202313:30GLOBEApollomics Announces Two New Cohorts in Global Phase 2..
26/10/202314:50GLOBEApollomics Announces Report of Activity of Vebreltinib in..
23/10/202314:30GLOBEApollomics Announces Efficacy of Vebreltinib in NSCLC..
17/10/202300:55GLOBEApollomics Announces Presentations of Vebreltinib Data at..
28/9/202322:17GLOBEApollomics Reports First Half 2023 Financial Results and..
06/9/202313:00GLOBEApollomics to Present at the H.C. Wainwright 25th Annual..

Dernières Valeurs Consultées

NASDAQ
APLMW
Apollomics
EU
MOP
Palmboomen Cultuur Maats...
LSE
1PLT
1x Pltr
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés